VWF levels were measured after a 24h-long DDAVP test. The rate constants considered were: k 0 , associated with the VWF release phase; k 1 , illustrating the phase of conversion from high-to lowmolecular-weight VWF multimers; k e , associated with the VWF elimination phase. The amount of VWF released (D) was also measured.
INTRODUCTION
Von Willebrand factor (VWF) contributes to haemostasis by mediating platelet adhesion and platelet aggregation at the site of vascular injury (1, 2) . VWF is a polymeric glycoprotein synthesised and stored in the form of ultra-large (UL) multimers in megakaryocytes (alpha granules) and endothelial cells (Weibel-Palade bodies) (3) . VWF may be released from alpha granules on platelet activation, and from Weibel Palade bodies on vascular injury, or under various physiological (4, 5) and pharmacological stimuli (e.g. desmopressin) (6) (7) (8) . Endothelial cells secrete VWF continuously to maintain basal plasma VWF levels (5) . VWF function is modulated by its multimer organisation: large and ultra-large VWF multimers have the greatest haemostatic effect, mainly due to their capacity to bind to platelets and sub-endothelial collagen during platelet plug formation; their absence is associated with a severe bleeding tendency (9) (10) (11) (12) . Low-molecularweight (LMW) multimers have a weaker haemostatic capacity, their main function being to carry FVIII, which does not require a full multimer organisation (13) . VWF released from endothelial cells undergoes extensive cleavage by circulating ADAMTS-13 protease, and this process gives rise to a heterogeneous VWF multimer pattern comprising high-molecular-weight (HMW) and LMW oligomers (14, 15) .
Quantitative and qualitative VWF defects lead to von Willebrand disease (VWD) (16, 17) , the most common inherited bleeding disorder. Quantitative VWF defects are associated with VWD types 1 and 3, and qualitative defects with types 2A, 2B, 2M and 2N. These various disease types are characterised by a different pathophysiology and bleeding risk (18, 19) . Several laboratory tests have been developed to identify and classify the different types of VWD (20) . VWF levels are quantified by means of an antigen assay (VWF:Ag), which is unable to distinguish between HMW and LMW multimers. VWF collagen binding (VWF:CB) (21) and VWF ristocetin cofactor activity (VWF:RCo) (22) are measured mainly to explore the haemostatically more efficient large VWF multimers and VWF binding to collagen in the former case, and platelet GPIb in the latter. Quantitative and functional tests can be used in combination to classify VWD patients by type (1, 2, 3) and subtype (2A, 2B, 2M, 2N) (23, 24) .
From a kinetic standpoint, plasma VWF levels and patterns of HMW and LMW multimers depend on the balance between three determinants: 1) the amount and rate of VWF release; 2) ADAMTS-13 proteolytic activity; and 3) VWF clearance from the plasma. These processes can be explored in detail by administering DDAVP, which induces an acute release of the VWF stored in the Weibel Palade bodies of endothelial cells, followed by proteolysis of the UL multimers and VWF clearance. This approach is currently used to explore VWF half-life (25) , and the simplest model employed to date consists of a bi-exponential function describing the rise and fall of plasma VWF:Ag and VWF:CB levels following desmopressin stimulation with the aid of a physiologybased mathematical model. This method can provide an estimate of the amount and rate of VWF release, in stimulated and basal conditions, and its clearance and half-life. It also enables us to characterise the VWF kinetics in normal individuals with the O and non-O blood groups (26) , and in some types of VWD (type 1, type 2B, type 3) (27) (28) (29) (30) . On the other hand, this method cannot quantify the proteolytic activity of ADAMTS-13, which is known to be higher in type 2A and 2B VWD than in normal subjects, and also in individuals in the O vis-à-vis the non-O blood groups.
Our team recently developed a more sophisticated pharmacokinetic (PK) model that can also account for proteolysis of the super ultra-large (SUL) VWF multimers adhering to the vessel wall, their conversion into smaller circulating molecules (SUL→HMW and SUL→LMW), and the biotransformation of HMW to LMW oligomers (31, 32) . The structural complexity of this model made it necessary to analyse pooled data on a homogeneous VWD population, however, or to obtain a large set of experimental data for each patient, in order to obtain a statistically reliable estimate of the pharmacokinetic parameters. We consequently simplified the original model and used it to analyse the time courses of VWF:Ag and VWF:CB plasma concentrations after DDAVP challenge in normal subjects and VWD patients known to have a short VWF half-life (type Vicenza) or abnormal proteolysis (types 2A and 2B). The aim of the present study was to ascertain 
MATERIALS AND METHODS
Patients and normal subjects were studied in accordance with the Helsinki Declaration, after obtaining their written informed consent, and our ethical board's approval of the study.
Haemostatic analysis. The main haemostatic findings in the patients involved were as reported elsewhere (33) . VWF antigen (VWF:Ag) was measured by enzyme-linked immunosorbent assay (ELISA) using horseradish peroxidase (HRP)-conjugated anti-VWF polyclonal antibody (Dako, Glostrup, Denmark). VWF collagen-binding (VWF:CB) activity was assessed with an ELISA test using type III collagen (Sigma, Milan, Italy). DDAVP (1-desamino-8-D-arginine vasopressin; Emosint, Sclavo, Italy) was administered subcutaneously at a dose of 0.3 µg/kg. Blood samples were collected before and 15, 30, 60, 120, 180, 240, 360 and 480 min, and 24 hours after administering DDAVP. The time courses of the VWF:Ag and VWF:CB plasma concentrations after the DDAVP challenge were analysed using our new mathematical model, which is described below and in the Results section. VWF multimers were analysed by electrophoresis on 1.8% high-gellingtemperature agarose containing 0.1% sodium dodecyl sulphate (27) . The multimers were detected by autoradiography after reaction with anti-VWF polyclonal antibody (DAKO) labelled with 125 -I and viewed with the DS-50000 Epson densitometer scanner.
Genetic analysis. Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The VWF gene exons, including the intron-exon boundaries, were amplified and sequenced using primers chosen according to the VWF sequence established by Mancuso et al (34) . The Big Dye Terminator Sequencing kit v.1.1 (Perkin Elmer, Wellesley, MA, USA) and an ABI 3130XL Genetic Analyzer (AB) were used for DNA sequencing. The procedures employed to determine the pharmacokinetic parameters in each subject are described in Appendix A.
RESULTS
Patients and healthy subjects. The study involved 9 patients with type Vicenza, 8 with type 2B, 2 with type 2A-I, and 1 with type 2A-II VWD, all genetically characterised. Their pertinent haemostatic and genetic details are given in Table 1 . Forty-two normal subjects (24 with blood group O and 18 with non-O blood groups) were enrolled as controls. The mean values of the PK parameters for normal subjects and VWD patients are listed in Table 2 and Table 3 , respectively. Figure 2 shows a graphical comparison between the estimated results for the different groups of subjects. (Table 2) were higher in the O than in the non-O blood group subjects, though the differences were only statistically significant for k e (p<0.0001) and D (p<0.005), and borderline significant for k 1 (p=0.051). There was no difference in the k 0 value between the blood groups ( Table 2 ). These findings suggest that blood group affects all the pathways explored except for the VWF release rate, and has a more marked effect on VWF clearance, confirming a previous report of a shorter VWF survival in subjects with the O blood group (26).
Type Vicenza VWD. All type Vicenza patients were carrying the p.R1205H mutation which, in all but two of them, was combined with the p.M740I variant. All the patients belonged to non-O blood groups except for the two carrying the p.R1205H mutation alone. All rate constants (k 0 , k 1 and k e , shown in Figure 2 ) were higher than in the controls, irrespective of ABO blood group. The k e parameter showed the highest value (p<0.00001), which was one order of magnitude higher than in controls (8.18+/-1.72 × 10 -3 vs 1.17+/-0.68 × 10 -3
, respectively) ( Tables 2, 3) ; the increases in k 0 and k 1 compared to controls were significant, but less pronounced (2.43-fold and 3.26-fold, respectively) than in k e ( Figure 2 ). The D parameter was statistically lower in patients than in controls (p<0.005). The most accelerated VWF pathway after DDAVP challenge in type Vicenza VWD was therefore clearance (k e ), though the other pathways were accelerated too, while the amount released (D) was lower.
Type 2B VWD. k 1 and k e were statistically greater in these patients than in controls ( Figure 2 ). The most pronounced increase concerned k 1 , which was one order of magnitude higher than in controls (47.1 +/-67.9 × 10 -4 vs 4.59 +/-6.40 × 10 -4 ); the increase in k e was smaller (2.76-fold), but the difference was still statistically significant (Table 2-3); k 0 was statistically lower; and D was indistinguishable from that of controls. According to our model, this implies a difference in the kinetics associated with VWF release in 2B subjects, where the same amount of VWF is released but over a longer time (a slower release rate). Clearly, the most accelerated pathway in this group concerns VWF proteolysis, with the pertinent k 1 value 10.2 times higher than in normal subjects -a (35) . In this form, the k 0, k 1 and D parameters tended to be lower than normal, though not to a statistically significant degree, whereas k e was indistinguishable from those of normal subjects. The one patient in our study with Type 2A-II -characterised by a mutation that makes VWF more sensitive to ADAMTS13 (36) -had a k 1 value 9.2 times higher than in controls and similar to the absolute value seen in type 2B VWD. The PK parameters related to the VWF release rate (k 0 ) or quantity (D) and clearance (k e ) did not differ significantly from those of normal subjects.
Multimer distribution. One important feature of the proposed mechanistic model is that it can be used to describe the multimer time courses in terms of UL+HMW and LMW species from variables are removed so quickly from the circulation by the action of ADAMTS13 that they are never detectable, while LMW multimers gradually increase to very high levels. In type Vicenza patients ( Figure 3d ) the model predicts a rapid disappearance of UL+HMW, just 2 hours after DDAVP administration, and of all the multimeric species within 6 hours, as a result of the accelerated clearance; and there are moderate LMW levels, as in normal subjects. These results clearly show that the multimer profiles predicted by the model are consistent with those obtained by gel electrophoresis in the subjects studied. In this regard, VWF:CB and its associated VWF:CB ratio reveal all their utility in the detection of VWF multimers, and its large components in particular (37) .
DISCUSSION
A simplified version of the mechanistic model described by Galvanin et al. (31) Three main PK parameters were studied: k 0 , which explores the pathway of VWF release from endothelial cells; k 1 , which elucidates the proteolytic conversion of large and ultra-large VWF multimers into LMW multimers; and k e , which represents the clearance of VWF from the circulation and consequently its plasma half-life. The amount of VWF released after DDAVP challenge was also measured with the D parameter.
Judging from the results obtained with our model, ABO blood group mainly affects two pathways,
i.e. VWF proteolysis and clearance, since the k 1 and k e were greater for subjects in the O than in the non-O blood groups. These findings are consistent with previous reports of healthy subjects with the O blood group having a shorter VWF survival (26) and lower circulating levels than non-O (38) , and a greater VWF susceptibility to ADAMTS13 (39) . While the increase in k e was statistically significant, the increase in k 1 closely approached the significance level (p=0.051).
This nearly-significant difference in k 1 suggests that the influence of ABO blood group on VWF proteolysis is weaker than on VWF survival (39) . If its impact on proteolysis were stronger, we would find relatively fewer large VWF multimers in O than in non-O individuals, but this has never been reported. It should be emphasised, however, that we found a marked variability in our population of normal subjects (n=42): this is hardly surprising, but might have influenced our results. Unlike our group's previous findings using a different PK model (26) , the amount of VWF released after DDAVP challenge was significantly higher in O than in non-O individuals. If our present observation holds, we might surmise that more VWF is stored in the Weibel-Palade bodies of healthy individuals with the O blood group. It has been previously reported, on the other hand, that VWF platelet content (which mimics endothelial cell condition) does not differ between ABO groups (40) . This goes to show that the contribution of ABO group in modulating circulating VWF in normal subjects is of interest not only per se, but also for its implication in the field of haemorrhagic and thrombotic disorders (41) .
Our model identified a high elimination rate (k e ) in type Vicenza VWD, which was the highest among all the patients studied here. This is consistent with the finding that a shorter VWF half-life is responsible for the significant reduction in circulating VWF levels, despite a normal VWF synthesis (27) . The p.R1205H mutation in the D3 domain of type Vicenza patients speeds up the clearance of VWF to such a degree that the circulating VWF levels are similar to those of severe type 1 VWD, i.e. often below 10 U/dL. Type Vicenza VWD often (but not always) features the presence of unusually large VWF multimers. This has been attributed by Gezsi et al (42) to a very short VWF half-life, which does not give ADAMTS13 time enough to cleave the ultra-large/large VWF multimers released by endothelial cells. Our findings confirm this hypothesis, since our patients' rate of conversion from UL+HMW to LMW VWF multimers (expressed by the k 1 parameter) seemed to be higher than normal, but less so than the increase in the k e parameter. The (Figure 1b) and VWF:CB (Figure 1c ) (about 0.5 h) with those obtained for the other groups of subjects (always about 2 h), and this finding has already been reported in the literature (27) . The second result is novel and warrants further investigation. According to our mechanistic model, all the biochemical pathways explored by our mechanistic model, i.e. VWF release, proteolysis and clearance, in particular, appear to be accelerated in type Vicenza, confirming that the main pathological issue in this condition is a very short VWF half-life. An explanation for this picture might be that the intrinsic defect in type Vicenza VWD -the p.R1205H mutation -prompts a generalised acceleration of all the biochemical pathways, or else that a faster clearance influences the other pathways.
In type 2B VWD patients, k 1 and k e were both significantly higher than normal, the former more so than the latter (k 1 was one order of magnitude higher than in controls), so the proteolytic pathway appears to be the prevalent one. This explains the lack of large VWF multimers in such patients.
The increase in k e confirms the shorter VWF half-life reported in patients with type 2B VWD (28).
An increased proteolysis and a decreased VWF survival both contribute to the type 2B VWD phenotype (28, 43) , though this is particularly true in type 2B patients lacking in large VWF multimers (44) . The two aspects may be dissociated, however, as seen in type 2B patients who still have large multimers, albeit with an apparently shorter VWF half-life (44) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 13 patients. In the two type 2A-I VWD patients all PK parameters, except k e, tended to be lower than in healthy controls, but the difference was not statistically significant. This picture is in line with these patients' defective VWF synthesis and multimerisation, as confirmed by their reduced plasma and platelet VWF levels, and shortage of large VWF multimers.
Our results can be summarised as follows: i) the magnitude of the VWF release rate constant k 0 significantly lower than normal in type 2B and 2.43 higher in type Vicenza VWD, suggesting an accelerated VWF release pathway in this variant of the disease;
ii) k 1 (a measure of the proteolytic conversion of HMW to LMW multimers) was greater than normal in type 2B and type 2A-II (which explains the lack of large VWF multimers). It was also greater, though less markedly so, in type Vicenza patients;
iii) k e (a measure of the VWF clearance rate) was very high in type Vicenza, consistently with the much reduced VWF half-life in this form of VWD; it was higher than normal in type 2B too (though to a lesser extent).
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Bullet points
What is known in this topic -Reduced VWF synthesis or survival, or increased proteolysis may contribute to VWD.
-The diagnosis and characterization of VWD is often complicated, and not always successful.
What this paper adds -A mechanistic model is proposed for exploring the release, proteolysis and elimination of VWF in patients with type 2A, 2B and type Vicenza VWD.
-In each form of VWD, the abnormality of one pathway seems to prevail over the others, thus explaining the associated phenotype.
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